JP6178843B2 - 透過性グリコシダーゼインヒビターおよびその用途 - Google Patents

透過性グリコシダーゼインヒビターおよびその用途 Download PDF

Info

Publication number
JP6178843B2
JP6178843B2 JP2015511546A JP2015511546A JP6178843B2 JP 6178843 B2 JP6178843 B2 JP 6178843B2 JP 2015511546 A JP2015511546 A JP 2015511546A JP 2015511546 A JP2015511546 A JP 2015511546A JP 6178843 B2 JP6178843 B2 JP 6178843B2
Authority
JP
Japan
Prior art keywords
optionally substituted
tetrahydro
pyrano
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015511546A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015516420A (ja
JP2015516420A5 (hr
Inventor
セルニツク,ハロルド,ジー
リー,ウエンピン
ホステトラー,エリツク
リユウ,クン
マツキーチヤン,アーネスト,ジエイ
ジヨウ、ユエンシイ
ウエイ,ジヨーンヨーン
ムウ,チヤンウエイ
ワン、ヤオドウ
チヤン、ジアーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2012/075185 external-priority patent/WO2013166654A1/en
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2015516420A publication Critical patent/JP2015516420A/ja
Publication of JP2015516420A5 publication Critical patent/JP2015516420A5/ja
Application granted granted Critical
Publication of JP6178843B2 publication Critical patent/JP6178843B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2015511546A 2012-05-08 2013-05-03 透過性グリコシダーゼインヒビターおよびその用途 Active JP6178843B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2012/075185 WO2013166654A1 (en) 2012-05-08 2012-05-08 Permeable glycosidase inhibitors and uses thereof
CNPCT/CN2012/075185 2012-05-08
US201261655641P 2012-06-05 2012-06-05
US61/655,641 2012-06-05
PCT/US2013/039377 WO2013169576A1 (en) 2012-05-08 2013-05-03 Permeable glycosidase inhibitors and uses thereof

Publications (3)

Publication Number Publication Date
JP2015516420A JP2015516420A (ja) 2015-06-11
JP2015516420A5 JP2015516420A5 (hr) 2016-06-23
JP6178843B2 true JP6178843B2 (ja) 2017-08-09

Family

ID=49551168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015511546A Active JP6178843B2 (ja) 2012-05-08 2013-05-03 透過性グリコシダーゼインヒビターおよびその用途

Country Status (10)

Country Link
US (1) US9611275B2 (hr)
EP (1) EP2847199B1 (hr)
JP (1) JP6178843B2 (hr)
KR (1) KR102108586B1 (hr)
CN (1) CN104395323B (hr)
AU (1) AU2013259892B2 (hr)
BR (1) BR112014027724B1 (hr)
CA (1) CA2871920C (hr)
RU (1) RU2707292C2 (hr)
WO (1) WO2013169576A1 (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079868B2 (en) 2008-08-01 2015-07-14 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2011140640A1 (en) 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
JP5861194B2 (ja) 2010-12-23 2016-02-16 アレクトス・セラピューティクス・インコーポレイテッド 選択的グルコシダーゼインヒビターおよびその使用
US8927507B2 (en) 2011-03-24 2015-01-06 Ernest J. McEachern Selective glycosidase inhibitors and uses thereof
US9718854B2 (en) 2011-03-31 2017-08-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000084A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) 2011-06-27 2017-07-11 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2726468B1 (en) 2011-06-27 2017-04-12 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9670195B2 (en) 2012-08-31 2017-06-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9809537B2 (en) 2012-08-31 2017-11-07 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
KR102205234B1 (ko) 2013-06-11 2021-01-20 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 SC-β 세포 및 조성물 그리고 그 생성 방법
WO2016073693A2 (en) 2014-11-05 2016-05-12 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
EP3458589A4 (en) 2016-05-18 2020-01-01 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. ハンチントン病治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CN109160873A (zh) * 2018-08-14 2019-01-08 重庆市化工研究院 一种芳香族烯丙基醚及其合成方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1441749A1 (ru) * 1987-03-16 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна 2-АМИНО-5,5-ДИМЕТИЛ-4,5-ДИГИДРО-7Н-ПИРАНО [4,3-d] ТИАЗОЛ, ОБЛАДАЮЩИЙ ТРАНКВИЛИЗИРУЮЩЕЙ АКТИВНОСТЬЮ
US20080166323A1 (en) 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
CA2599843C (en) 2005-03-01 2013-08-27 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
CN101595111A (zh) * 2006-08-31 2009-12-02 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
WO2008025170A1 (en) * 2006-08-31 2008-03-06 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US9079868B2 (en) 2008-08-01 2015-07-14 Simon Fraser University Selective glycosidase inhibitors and uses thereof
AU2009276222B2 (en) 2008-08-01 2015-03-05 Simon Fraser University Selective glycosidase inhibitors and uses thereof
AU2009299073B2 (en) 2008-09-16 2015-04-02 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2011140640A1 (en) * 2010-05-11 2011-11-17 Simon Fraser University Selective glycosidase inhibitors and uses thereof
TW201249848A (en) * 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012159262A1 (en) * 2011-05-24 2012-11-29 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2744338B1 (en) * 2011-08-18 2016-04-27 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof

Also Published As

Publication number Publication date
CN104395323B (zh) 2017-08-01
CN104395323A (zh) 2015-03-04
EP2847199A1 (en) 2015-03-18
JP2015516420A (ja) 2015-06-11
KR20150006841A (ko) 2015-01-19
EP2847199A4 (en) 2015-11-11
US9611275B2 (en) 2017-04-04
KR102108586B1 (ko) 2020-05-07
BR112014027724A2 (hr) 2017-08-22
CA2871920A1 (en) 2013-11-14
WO2013169576A1 (en) 2013-11-14
AU2013259892B2 (en) 2017-09-14
AU2013259892A1 (en) 2014-10-30
RU2707292C2 (ru) 2019-11-26
US20150152127A1 (en) 2015-06-04
BR112014027724B1 (pt) 2022-05-03
RU2014149183A (ru) 2016-06-27
CA2871920C (en) 2021-03-09
EP2847199B1 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
JP6178843B2 (ja) 透過性グリコシダーゼインヒビターおよびその用途
JP6147737B2 (ja) 選択的グリコシダーゼ阻害剤およびその使用
AU2016202186B2 (en) Selective glycosidase inhibitors and uses thereof
JP5771237B2 (ja) 選択的グリコシダーゼ阻害剤およびその使用
RU2672873C2 (ru) Ингибиторы гликозидаз и их применения
EP2744338B1 (en) Selective glycosidase inhibitors and uses thereof
US8927507B2 (en) Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) Selective glycosidase inhibitors and uses thereof
HUE030624T2 (en) Selective glycosidase inhibitors and their use
US8901087B2 (en) Selective glycosidase inhibitors and uses thereof
WO2013166654A1 (en) Permeable glycosidase inhibitors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170714

R150 Certificate of patent or registration of utility model

Ref document number: 6178843

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250